Vazyme(SH:688105) Xin Lang Cai Jing·2025-12-24 01:36Group 1 - The core business of the company includes research and development of functional proteins and high molecular organic materials, with a focus on biological reagents, in vitro diagnostics, and antibody drug development [2] - As of September 30, the company reported a total revenue of 952 million yuan for the first nine months of 2025, a year-on-year decrease of 3.40%, and a net profit attributable to shareholders of 6.6152 million yuan, down 63.57% year-on-year [2] - The company has a total of 9,447 shareholders, which is an increase of 9.90% compared to the previous period, while the average circulating shares per person decreased by 9.01% to 42,101 shares [2] Group 2 - The company has distributed a total of 731 million yuan in dividends since its A-share listing, with 611 million yuan distributed over the past three years [3] Group 3 - On December 23, the company's stock price fell by 1.16%, with a trading volume of 32.5978 million yuan [1] - The financing buy-in amount on December 23 was 5.6547 million yuan, with a net financing buy-in of 512,800 yuan, bringing the total financing and securities balance to 123 million yuan [1] - The company's financing balance accounts for 1.58% of its circulating market value and is at a high level, exceeding the 90th percentile over the past year [1] - On the same day, the company had a short selling amount of 48,000 shares, with a total short selling value of 94,300 yuan, while the short selling balance was 188,600 yuan, which is below the 10th percentile over the past year [1]